LCN2 and acute kidney injury: Based on the findings that have been discussed, some FABPs have shown good significance and are able to match the capabilities of existing biomarkers, such as L-FABP as a biomarker to distinguish patients with progressive AKI and cirrhosis, which has comparable abilities to NGAL, IL-18, and albumin as other candidate biomarkers [26].